Low-dose rapamycin for familial adenomatous polyposis
Part of Cancer, Digestive system, Genetic & congenital clinical trials.
This trial provides early access to an experimental drug called eRapa (a low dose of rapamycin) for people with familial adenomatous polyposis (FAP). The drug may help slow or reduce polyp growth, possibly delaying or avoiding surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have finished growing and are past puberty.
- You have FAP confirmed by a genetic test or a family history in a parent.
- You have a significant number of polyps in your colon, rectum, or duodenum.
- You must not have active cancer or high-grade dysplasia in your GI tract.
- You must not have a MUTYH gene mutation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called eRapa for people with Familial Adenomatous Polyposis (FAP), a condition that causes many polyps in the colon and raises the risk of cancer. The goal is to see if eRapa can help reduce polyps and improve outcomes.
This study tests a new drug called ST316 to see if it can help people with familial adenomatous polyposis (FAP), a condition that causes many polyps in the colon. The goal is to reduce the number or size of these polyps to lower the risk of cancer.
This trial tests whether taking vitamin B1 can help people with familial adenomatous polyposis (FAP) reduce the number of polyps in their colon or rectum. It is designed for people who still have most of their bowel and have more than 10 polyps.
This trial tests if a drug called rapamycin can help reduce polyps in teenagers with a condition that causes many polyps in the colon. It aims to see if the drug is safe and might help prevent the need for surgery.
This early-phase trial studies REC-4881 in adults with familial adenomatous polyposis (FAP), a condition that causes many colon/rectum and duodenal polyps. It aims to see whether the treatment can safely help control or shrink polyp growth in people who have had bowel surgery.
This trial tests a new drug, TPST-1495, to reduce the number of benign polyps in the small intestine for people with a condition called familial adenomatous polyposis (FAP). If you join, you will likely not know if you receive the drug or a placebo, to see if the drug is helpful.
Hear when a new Familial Adenomatous Polyposis (FAP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.